Name	I034
Target	IKZF1/3					Target Info
Structure
				2D MOL
Isosmiles	OC1(CCC1)C(N2CCC(N3C=C(CC4=CC=C5N(C(C6=CC=CC4=C56)=O)C7CCC(NC7=O)=O)C=N3)CC2)=O

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half Maximal Inhibitory Concentration (IC50)	0.007	nM	NCI-H929 cells	Multiple myeloma	CVCL_1600
Half Maximal Degradation Concentration (DC50)	0.024	nM	NCI-H929 cells	Multiple myeloma	CVCL_1600
Half Maximal Degradation Concentration (DC50)	<0.05	nM	PBMC cells	Normal	CVCL_0140
Half Maximal Degradation Concentration (DC50)	0.092	nM	MM.1S cells	Multiple myeloma	CVCL_8792

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	90.41%
In Vivo Model	NCI-H929 CDX 3 mpk (Day 25)
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	98.82%
In Vivo Model	NCI-H929 CDX 6 mpk (Day25)

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01669 nM
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Degradation Concentration (DC50)	0.06 nM
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Degradation Concentration (DC50)	13.06 nM
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99.94%
In Vivo Model	NCI-H929 CDX 3 mpk (Day 25)
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100%
In Vivo Model	NCI-H929 CDX 6 mpk (Day25)

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.00269 nM
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.00941 nM
In Vitro Model	Plasma cell myeloma, Multiple myeloma	MM.1S cells		CVCL_8792
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Degradation Concentration (DC50)	0.075 nM
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Degradation Concentration (DC50)	13.8 nM
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.0183 nM
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.0776 nM
In Vitro Model	Plasma cell myeloma, Multiple myeloma	MM.1S cells		CVCL_8792
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.0540 nM
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600

Ref 1	Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy